1Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer,2004,5 Suppl 2: S51-55.
2Thodtmann R, Depenbrock H, Dumez H,et al. Clinical and pharmacokinetic phase Ⅰ study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol,1999,17(10): 3009-3016.
3Vogelzang NJ, Rusthoven J J, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleuralmesothelioma. J Clin Oncol, 2003, 21(14): 2636-2644.
4Smit EF, Mattson K, von Pawel J, et al.ALIMTA (pemetrexed disodium) as second-line treatment of non-small- cell lung cancer: a phase Ⅱ study. Ann Oncol,2003,14(3) :455-460.
5Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously trea ted with chemotherapy. J Clin Oncol,2004,22(9) : 1589-1597.
6Rusthoven J J, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase Ⅱ study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol,1999,17(4) :1194.
7Clarke SJ, Abratt R, Goedhals L, et al.Phase Ⅱ trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapynaive patients with advanced non-small-cell lung cancer. Ann Oncol, 2002, 13 (5) :737-741.
8Manegold C, Gatzemeier U, von Pawel J,et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase Ⅱ trial. Ann Oncol,2000,11(4) : 435-440.
9Scagliotti GV. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. Semin Oncol,2005,32(2 Suppl 2) :S5-S8.
10Monnerat C, Le Chevalier T, Kelly K, et al. Phase Ⅱ study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer.Clin Cancer Res, 2004, 10 (16) : 5439-5446.
10Suwanrusme H,Meyer ML,Green MR.Pemetrexed alone and in combinationwith platinum compounds in the management of malignant mesothelioma[J].Clin Lung Cancer,2004,5(2):56-60.
